Parvovirus B19 VLP VP1/VP2 Co-Capsid

recombinant, Sf9 insect cells

Catálogo Nº Apresentação Preço (R$) Comprar / Observação
PR-1276 20 μg Sob demanda Adicionar ao Carrinho

For general laboratory use.

Envio: shipped on gel packs

Condições de armazenamento: store at -20 °C
avoid freeze/thaw cycles

Validade: 12 months

Pureza: > 80 % (SDS-PAGE)

Forma: liquid (Supplied in 16 mM sodium phosphate pH 7.4, 120 mM NaCl and 20% glycerol)

Formulários:
Western Blot with anti-Parvovirus B19 positive sera. Binds IgG-type human antibodies.

Descrição:
Recombinant Parvovirus B19 VLP VP1/VP2 Co-Capsid is produced in SF9 containing B19 capsid proteins VP1 (86,049 Dalton) and VP2 (60,839 Dalton). The B19 virus, usually referred to as parvovirus B19 or sometimes as erythrovirus B19, belongs to the family of parvoviruses, genus erythrovirus. B19 virus causes a childhood rash named 'fifth disease' or 'erythema infectiosum' which is ordinarily known as 'slapped cheek syndrome'. Erythroviruses are members of the Parvoviridae family of small DNA viruses. The B19 virus is a non-enveloped, icosahedral virus which contains a single-stranded linear DNA genome. Parvovirus B19 is classified as erythrovirus because of its capability to invade red blood cell precursors in the bone marrow. This virus is mainly spread by infected respiratory droplets, though, blood-borne transmission has also been reported.

Referências selecionadas:
Sico et al. (2002) Enhanced kinetic extraction of parvovirus B19 structural proteins. Biotechnol Bioeng. 80:250.